ClinicalTrials.gg
CompletedNCT03703466Updated Apr 2, 2024Results posted

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

A Phase 2 interventional study of Abemaciclib in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
35th of 55
72 · median 120
Started
2018
the only one that year
Phase 2
27 of 55
12 open now
Registered
15th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 35th largest by enrollment, is the only one that started in 2018, is one of 27 in phase 2, and was the 15th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HR+, - breast cancer (mBC).
  • Have all of the following:

    • Recurrent, locally advanced, unresectable or mBC with disease progression following anti-estrogen therapy.
    • Prior treatment with chemotherapy for locally advanced or metastatic disease.
    • No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.
  • Have performance status (ECOG PS) ≤1.
  • Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
  • Have adequate organ function.
  • Women of must have a negative pregnancy test.
  • Are able to swallow tablets/capsules.

Exclusion criteria

Exclusion Criteria:

  • Are currently receiving treatment in a clinical study involving an product.
  • Have a serious concomitant systemic disorder.
  • Have symptomatic central nervous system (CNS) or .
  • Have a symptomatic (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
  • Have a personal history of syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
  • Have a history of any other cancer.
  • Had major surgery within 14 days prior to randomization.
  • Are breastfeeding.
  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    200 mg Abemaciclib With a Meal

    200 mg abemaciclib given twice a day (BID) orally with a meal.

    Drug: Abemaciclib

  • Experimental
    200 mg Abemaciclib Without a Meal

    200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.

    Drug: Abemaciclib

  • Experimental
    200 mg Abemaciclib Without Regard to Food

    200 mg abemaciclib given twice a day (BID) orally without regard for food.

    Drug: Abemaciclib

Interventions

  • Administered orally.

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Severe Diarrhea (≥ Grade 3)

    Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).

    Time frame: Cycle 3 (28 Days Cycle)

  2. Percentage of Participants With Prolonged Grade 2 Diarrhea

    Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.

    Time frame: Cycle 3 (28 Days Cycle)

  3. Percentage of Participants With Dose Reductions Due to Diarrhea

    Percentage of participants with dose reductions due to diarrhea during first 3 cycles.

    Time frame: Cycle 3 (28 Days Cycle)

  4. Percentage of Participants With Dose Interruptions Due to Diarrhea

    Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.

    Time frame: Cycle 3 (28 Days Cycle)

  5. Percentage of Participants Who Discontinue Treatment Due to Diarrhea

    Percentage of participants who discontinue treatment due to diarrhea

    Time frame: Cycle 3 (28 Days Cycle)

  6. Percentage of Participants Utilizing Antidiarrheals

    Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.

    Time frame: Cycle 3 (28 Days Cycle)

Secondary outcomes

  1. Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

    PK: Mean steady state exposure of abemaciclib

    Time frame: Cycle 1: Day 15; Cycle 2: Day 1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

  2. PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567

    PK: Mean steady state exposure of abemaciclib metabolite LSN2839567

    Time frame: Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

  3. PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726

    PK: Mean steady state exposure of abemaciclib metabolite LSN3106726

    Time frame: Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

07

Results

Posted Aug 13, 2020

Participant flow

Participant flow — Overall Study
Milestone200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Started242424
Received at least one dose of study drug242324
Completed201822
Not completed462
Withdrew: Death210
Withdrew: Withdrawal by subject030
Withdrew: Completed < 3 cycles222

Outcome measures

PrimaryPercentage of Participants With Severe Diarrhea (≥ Grade 3)

Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants With Severe Diarrhea (≥ Grade 3)
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants With Severe Diarrhea (≥ Grade 3)4.200
PrimaryPercentage of Participants With Prolonged Grade 2 Diarrhea

Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants With Prolonged Grade 2 Diarrhea
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants With Prolonged Grade 2 Diarrhea8.317.420.8
PrimaryPercentage of Participants With Dose Reductions Due to Diarrhea

Percentage of participants with dose reductions due to diarrhea during first 3 cycles.

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants With Dose Reductions Due to Diarrhea
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants With Dose Reductions Due to Diarrhea16.78.712.5
PrimaryPercentage of Participants With Dose Interruptions Due to Diarrhea

Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants With Dose Interruptions Due to Diarrhea
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants With Dose Interruptions Due to Diarrhea16.74.38.3
PrimaryPercentage of Participants Who Discontinue Treatment Due to Diarrhea

Percentage of participants who discontinue treatment due to diarrhea

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinue Treatment Due to Diarrhea
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants Who Discontinue Treatment Due to Diarrhea000
PrimaryPercentage of Participants Utilizing Antidiarrheals

Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.

Time frame:
Cycle 3 (28 Days Cycle)
Reported as:
Number · percentage of participants
Percentage of Participants Utilizing Antidiarrheals
percentage of participants200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Percentage of Participants Utilizing Antidiarrheals95.891.395.8
SecondaryPharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

PK: Mean steady state exposure of abemaciclib

Time frame:
Cycle 1: Day 15; Cycle 2: Day 1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
nanogram/milliliter (ng/mL)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Cycle 1: Day 15305 ± 198369 ± 64356 ± 75
Cycle 2: Day 1320 ± 91280 ± 99190 ± 284
Cycle 2: Day 1577.4 ± 731345 ± 51223 ± 250
Cycle 3: Day 1135 ± 896330 ± 5485.4 ± 498
SecondaryPK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567

PK: Mean steady state exposure of abemaciclib metabolite LSN2839567

Time frame:
Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567
nanogram/milliliter (ng/mL)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Cycle 1 Day 15139 ± 109129 ± 48159 ± 61
Cycle 2 Day 1125 ± 62109 ± 8496.3 ± 127
Cycle 2 Day 1550.4 ± 276121 ± 45112 ± 79
Cycle 3 Day 189.4 ± 110125 ± 4861.7 ± 122
SecondaryPK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726

PK: Mean steady state exposure of abemaciclib metabolite LSN3106726

Time frame:
Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726
nanogram/milliliter (ng/mL)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
Cycle 1 Day 15231 ± 120242 ± 38287 ± 63
Cycle 2 Day 1230 ± 59210 ± 57152 ± 222
Cycle 2 Day 1580.5 ± 377221 ± 31182 ± 112
Cycle 3 Day 1146 ± 174223 ± 33107 ± 172

Adverse events

Collected over Baseline until end of the follow-up (Up To 44 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Abemaciclib With a Meal3/24 (12.5%)3/24 (12.5%)24/24 (100%)
200 mg Abemaciclib Without a Meal4/23 (17.4%)5/23 (21.7%)23/23 (100%)
200 mg Abemaciclib Without Regard to Food1/24 (4.2%)8/24 (33.3%)24/24 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
Event200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
NauseaGastrointestinal disorders0/243/230/24
VomitingGastrointestinal disorders1/242/230/24
Pleural effusionRespiratory, thoracic and mediastinal disorders0/240/232/24
Hepatic function abnormalHepatobiliary disorders0/241/230/24
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/241/230/24
Superficial vein thrombosisVascular disorders0/241/230/24
AnaemiaBlood and lymphatic system disorders0/240/231/24
Atrial fibrillationCardiac disorders0/240/231/24
DiarrhoeaGastrointestinal disorders1/240/231/24
PancreatitisGastrointestinal disorders0/240/231/24
Most frequent other events
Showing 10 of 185
Most frequent other events
Event200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to Food
DiarrhoeaGastrointestinal disorders21/2422/2322/24
NauseaGastrointestinal disorders15/2411/2314/24
AnaemiaBlood and lymphatic system disorders14/2411/2310/24
FatigueGeneral disorders11/244/2310/24
Platelet count decreasedInvestigations11/247/235/24
VomitingGastrointestinal disorders10/2410/237/24
Abdominal painGastrointestinal disorders10/244/235/24
Neutrophil count decreasedInvestigations7/246/2310/24
NeutropeniaBlood and lymphatic system disorders6/248/239/24
White blood cell count decreasedInvestigations9/247/237/24

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to FoodTotal
Mean58.2 ± 11.656.9 ± 11.157.6 ± 8.357.6 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to FoodTotal
Female23242471
Male1001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to FoodTotal
Hispanic or Latino0011
Not Hispanic or Latino24192063
Unknown or Not Reported0538
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to FoodTotal
American Indian or Alaska Native0000
Asian2002
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White22242470
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)200 mg Abemaciclib With a Meal200 mg Abemaciclib Without a Meal200 mg Abemaciclib Without Regard to FoodTotal
Turkey66618
Belgium0101
Australia11101031
Spain66719
Russia1113
08

Study locations

15 sites
  • Mater Private Hospital
    North Sydney, New South Wales 2291, Australia
  • St Vincent's Hospital
    Sydney, New South Wales 2010, Australia
  • Ashford Cancer Centre Research
    Kurralta Park, South Australia 5037, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Russian Oncological Research Center
    Moscow, 115478, Russian Federation
  • Volgograd regional clinical oncology dispensary
    Volgograd, 400138, Russian Federation
  • Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga
    Barcelona, 08023, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Ruber Internacional
    Madrid, 28034, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Akdeniz University Medical Faculty
    Antalya, 07058, Turkey
  • Trakya University Faculty of Medicine
    Edirne, 22030, Turkey
  • Medical Park Izmir Hospital
    Izmir, 35575, Turkey
  • Inonu University Medical Faculty
    Malatya, 44280, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jul 2019, 8 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 8 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2018
First posted
Oct 12, 2018
StartActual
Nov 28, 2018
Primary completionActual
Jul 29, 2019
CompletionActual
Mar 9, 2023
Results first posted
Aug 13, 2020
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03703466
Responsible party
Sponsor
First posted
Oct 12, 2018
Start date
Nov 28, 2018
Primary completion
Jul 29, 2019
Completion
Mar 9, 2023
Results posted
Aug 13, 2020
Last update
Apr 2, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion